Antiretroviral drugs in pediatric HIV-infected patients: Pharmacokinetic and practical challenges

Pediatric Drugs

Volumn 13, Issue 3, 2011, Pages 175-192

  Phelps, B Ryan ^a,b   Rakhmanina, Natella ^a,c  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Abacavir; Antiretrovirals; Atazanavir; Children; Darunavir; Didanosine; Efavirenz; Emtricitabine; Enfuvirtide; Etravirine; Fosamprenavir; HIV infections; Indinavir; Integrase inhibitors; Lamivudine; Lopinavir; Maraviroc; Nelfinavir; Nevirapine; Non nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Peptide hydrolase inhibitors; Raltegravir; Ritonavir; Saquinavir; Stavudine; Tenofovir disoproxil fumarate; Tipranavir; Zidovudine

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; INTEGRASE INHIBITOR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RIFAMPICIN; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNINDEXED DRUG; ZIDOVUDINE;

ADULT; ANEMIA; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; BEDTIME DOSAGE; CHILDHOOD DISEASE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG METABOLISM; DRUG STORAGE; FOOD DRUG INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; NEPHROLITHIASIS; NEPHROTOXICITY; NEUROTOXICITY; OSTEOPOROSIS; PALATABILITY; PANCREATITIS; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW; TOXIC HEPATITIS;

ANTI-HIV AGENTS; CHILD; HIV INFECTIONS; HUMANS; TECHNOLOGY, PHARMACEUTICAL;

EID: 79955122994     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.2165/11587300-000000000-00000     Document Type: Review

References (141)

1. UNAIDS. Report on the global HIV/AIDS epidemic 2009. New York: UNAIDS, 2009
2. Newell ML, Coovadia H, Cortina-Borja M, et al. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 2004; 364 (9441): 1236-43 (Pubitemid 39311344)
3. Patel K, Hernan MA, Williams PL, et al. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. Clin Infect Dis 2008; 46 (4): 507-15 (Pubitemid 351263487)
4. Sutcliffe CG, van Dijk JH, Bolton C, et al. Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa. Lancet Infect Dis 2008; 8 (8): 477-89 (Pubitemid 352005822)
5. WHO, UNAIDS, UNICEF. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report, September 2009. Geneva: WHO, 2009
6. Waning B, Diedrichsen E, Jambert E, et al. The global pediatric antiretroviral market: analyses of product availability and utilization reveal challenges for development of pediatric formulations and HIV/AIDS treatment in children. BMC Pediatr 2010; 10 (1): 74-88
7. Holmes CB, Coggin W, Jamieson D, et al. Use of generic antiretroviral agents and cost savings in PEPFAR treatment programs. JAMA 2010; 304 (3): 313-20
8. Gupta RK, Gibb DM, Pillay D. Management of paediatric HIV-1 resistance. Curr Opin Infect Dis 2009; 22 (3): 256-63
9. Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection (updated August 16, 2010) [online]. Available from URL: http:// aidsinfo.nih.gov/contentfiles/PediatricGuidelines.pdf [Accessed 2011 Jan 1]
10. WHO. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach, 2003 revision. Geneva: WHO, 2003
11. WHO. Antiretroviral therapy of HIV infection in infants and children: toward universal access. Recommendations for a public health approach, 2006. Geneva: WHO, 2006
12. WHO. Antiretroviral therapy of HIV infection in infants and children: toward universal access. Recommendations for a public health approach, 2010. Geneva: WHO, 2010
13. WHO. HIV/AIDS: guidelines [online]. Available from URL: . who.int/hiv/pub/guidelines/en/ [Accessed 2011 Apr 6]
14. Welch S, Sharland M, Lyall EG, et al. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. PENTA Steering Committee. HIV Med 2009 Nov; 10 (10): 591-613
15. WHO. HIV/AIDS guidelines [online]. Available from URL: . who.int/hiv/pub/guidelines/en/ [Accessed 2011 Mar 30]
16. Paediatric European Network for Treatment of AIDS. Treatment guidelines 2009 [online]. Available from URL: lines.htm [Accessed 2011 Mar 30]
17. AIDSinfo. Clinical guidelines portal [online]. Available from URL: http:// www.aidsinfo.nih.gov/guidelines/ [Accessed 2011 Mar 30]
18. Pollock L, Else L, Poerksen G, et al. Pharmacokinetics of nevirapine in HIVinfected children with and without malnutrition receiving divided adult fixed-dose combination tablets. J Antimicrob Chemother 2009; 64 (6): 1251-9
19. Stevens RC, Rodman JH, Yong FH, et al. Effect of food and pharmacokinetic variability on didanosine systemic exposure in HIV-infected children. Pediatric AIDS Clinical Trials Group Protocol 144 Study Team. AIDS Res Hum Retroviruses 2000; 16 (5): 415-21 (Pubitemid 30193809)
20. Mueller BU, Butler KM, Stocker VL, et al. Clinical and pharmacokinetic evaluation of long-term therapy with didanosine in children with HIV infection. Pediatrics 1994; 94 (5): 724-31 (Pubitemid 24326513)
21. Abreu T, Plaisance K, Rexroad V, et al. Bioavailability of once- and twicedaily regimens of didanosine in human immunodeficiency virus-infected children. Antimicrob Agents Chemother 2000; 44 (5): 1375-6 (Pubitemid 30228326)
22. Bazzoli C, Jullien V, Le Tiec C, et al. Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action. Clin Pharmacokinet 2010; 49 (1): 17-45
23. Capparelli EV, Englund JA, Connor JD, et al. Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children. J Clin Pharmacol 2003; 43 (2): 133-40 (Pubitemid 36125939)
24. Fletcher CV, Brundage RC, Remmel RP, et al. Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy. Antimicrob Agents Chemother 2000; 44 (4): 1029-34 (Pubitemid 30165286)
25. Hazra R, Gafni RI,Maldarelli F, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Pediatrics 2005; 116 (6): e846-54 (Pubitemid 46056464)
26. Fletcher CV, Kawle SP, Kakuda TN, et al. Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons. AIDS 2000; 14 (14): 2137-44
27. Capparelli EV, Mirochnick M, Dankner WM, et al. Pharmacokinetics and tolerance of zidovudine in preterm infants. J Pediatr 2003; 142 (1): 47-52 (Pubitemid 36106387)
28. Butler KM, Venzon D, Henry N, et al. Pancreatitis in human immunodeficiency virus-infected children receiving dideoxyinosine. Pediatrics 1993; 91 (4): 747-51 (Pubitemid 23115737)
29. Gafni RI, Hazra R, Reynolds JC, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics 2006; 118 (3): e711-8 (Pubitemid 46089998)
30. Hazra R, Balis FM, Tullio AN, et al. Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children. Antimicrob Agents Chemother 2004; 48 (1): 124-9 (Pubitemid 38040187)
31. Purdy JB, Gafni RI, Reynolds JC, et al. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr 2008; 152 (4): 582-4 (Pubitemid 351381047)
32. Kiser JJ, Carten ML, Aquilante CL, et al. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther 2008; 83 (2): 265-72
33. Goicoechea M, Liu S, Best B, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reversetranscriptase inhibitor-based therapy. J Infect Dis 2008; 197 (1): 102-8 (Pubitemid 351263473)
34. Camacho-Gonzalez AF, Ross AC, Chakraborty R. The clinical care of the HIV-1-infected infant. Clin Perinatol 2010; 37 (4): 873-85, xi
35. Kovacs A, Cowles MK, Britto P, et al. Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life. Pediatr Infect Dis J 2005; 24 (6): 503-9 (Pubitemid 40847522)
36. Cadilla A, Qureshi N, Johnson DC. Pediatric antiretroviral therapy. Expert Rev Anti Infect Ther 2010; 8 (12): 1381-402
37. LePrevost M, Green H, Flynn J, et al. Adherence and acceptability of once daily lamivudine and abacavir in human immunodeficiency virus type-1 infected children. Pediatr Infect Dis J 2006; 25 (6): 533-7 (Pubitemid 43863364)
38. McKinney Jr RE, Rodman J, Hu C, et al. Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021. Pediatrics 2007; 120 (2): e416-23 (Pubitemid 47219493)
39. Bergshoeff A, Burger D, Verweij C, et al. Plasma pharmacokinetics of onceversus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13). Antivir Ther 2005; 10 (2): 239-46 (Pubitemid 41151030)
40. PENTA. Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months. Antivir Ther 2010 15 (3) 297-305
41. Musiime V, Kendall L, Bakeera-Kitaka S, et al. Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial. Antivir Ther 2010; 15 (8): 1115-24
42. Rakhmanina NY, van den Anker JN. Efavirenz in the therapy of HIV infection. Expert Opin Drug Metab Toxicol 2009; 6 (1): 95-103
43. Dickinson L, Khoo S, Back D. Pharmacokinetic evaluation of etravirine. Expert Opin Drug Metab Toxicol 2010; 6 (12): 1575-85
44. Dahri K, Ensom MH. Efavirenz and nevirapine in HIV-1 infection: is there a role for clinical pharmacokinetic monitoring? Clin Pharmacokinet 2007; 46 (2): 109-32 (Pubitemid 46193057)
45. Chen J, Sun J, MaQ, et al. CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients. Ther Drug Monit 2010 Oct; 32 (5): 573-8
46. Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 2005; 15 (1): 1-5 (Pubitemid 43205520)
47. Zembruski NC, Haefeli WE, Weiss J. Interaction potential of etravirine with drug transporters assessed in vitro. Antimicrob Agents Chemother. Epub 2010 Dec 28
48. Kwara A, Ramachandran G, Swaminathan S. Dose adjustment of the nonnucleoside reverse transcriptase inhibitors during concurrent rifampicincontaining tuberculosis therapy: one size does not fit all. Expert Opin Drug Metab Toxicol 2010; 6 (1): 55-68
49. Pham PA, Flexner C. Emerging antiretroviral drug interactions. J Antimicrob Chemother 2011 Feb; 66 (2): 235-9
50. Capparelli E, Rakhmanina N,Mirochnick M. Pharmacotherapy of perinatal HIV. Semin Fetal Neonatal Med 2005; 10 (2): 161-75 (Pubitemid 40215543)
51. Leth FV, Kappelhoff BS, Johnson D, et al. Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy. AIDS Res Hum Retroviruses 2006; 22 (3): 232-9
52. Back D, Gibbons S, Khoo S. An update on therapeutic drug monitoring for antiretroviral drugs. Ther Drug Monit 2006; 28 (3): 468-73 (Pubitemid 44314939)
53. Gonzalez de Requena D, Bonora S, Garazzino S, et al. Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting. Antimicrob Agents Chemother 2005; 49 (9): 3966-9 (Pubitemid 41233062)
54. Fletcher CV, Brundage RC, Fenton T, et al. Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial. Clin Pharmacol Ther 2008; 83 (2): 300-6
55. Hirt D, Urien S, Olivier M, et al. Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children? Antimicrob Agents Chemother 2009; 53 (10): 4407-13
56. Ren Y, Nuttall JJ, Egbers C, et al. High prevalence of subtherapeutic plasma concentrations of efavirenz in children. J Acquir Immune Defic Syndr 2007; 45 (2): 133-6 (Pubitemid 46869804)
57. King JR, Acosta EP, Yogev R, et al. Steady-state pharmacokinetics of lopinavir/ ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients. Pediatr Infect Dis J 2009; 28 (2): 159-61
58. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15 (1): 71-5 (Pubitemid 32055781)
59. Wintergerst U, Hoffmann F, Jansson A, et al. Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children. J Antimicrob Chemother 2008; 61 (6): 1336-9 (Pubitemid 351753604)
60. Scherpbier HJ, Bekker V, Pajkrt D, et al. Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenzcontaining regimen. Pediatrics 2007; 119 (3): e705-15 (Pubitemid 46407545)
61. Kontorinis N, Dieterich DT. Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Semin Liver Dis 2003; 23 (2): 173-82
62. Scholler-Gyure M, Kakuda TN, Raoof A, et al. Clinical pharmacokinetics and pharmacodynamics of etravirine. Clin Pharmacokinet 2009; 48 (9): 561-74
63. King JR, Nachman S, Yogev R, et al. Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virusinfected children and adolescents: pediatric AIDS clinical trials group protocol 403. Pediatr Infect Dis J 2005; 24 (10): 880-5 (Pubitemid 41475922)
64. Krogstad P, Lee S, Johnson G, et al. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1. Clin Infect Dis 2002; 34 (7): 991-1001 (Pubitemid 34229769)
65. Burger DM, Bergshoeff AS, De Groot R, et al. Maintaining the nelfinavir trough concentration above 0.8 mg/L improves virologic response in HIV-1-infected children. J Pediatr 2004; 145 (3): 403-5 (Pubitemid 39165692)
66. Bergshoeff AS, Fraaij PL, van Rossum AM, et al. Pharmacokinetics of nelfinavir in children: influencing factors and dose implications. Antivir Ther 2003; 8 (3): 215-22 (Pubitemid 36960895)
67. Giaquinto C,Morelli E, Fregonese F, et al. Current and future antiretroviral treatment options in paediatric HIV infection. Clin Drug Investig 2008; 28 (6): 375-97 (Pubitemid 351695404)
68. Crommentuyn KM, Scherpbier HJ, Kuijpers TW, et al. Population pharmacokinetics and pharmacodynamics of nelfinavir and its active me- tabolite M8 in HIV-1-infected children. Pediatr Infect Dis J 2006; 25 (6): 538-43 (Pubitemid 43863365)
69. Sulkowski MS. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis 2004; 38 Suppl. 2: S90-7 (Pubitemid 38328170)
70. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents: a Working Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. (updated January 10, 2011) [online]. Available from URL: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf [Accessed 2011 Jan 1]
71. Burger DM, Hugen PW, Aarnoutse RE, et al. Treatment failure of nelfinavircontaining triple therapy can largely be explained by low nelfinavir plasma concentrations. Ther Drug Monit 2003 Feb; 25 (1): 73-80 (Pubitemid 36139829)
72. van Rossum AM, Dieleman JP, Fraaij PL, et al. Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1-infected children treated with indinavir. Pediatrics 2002; 110 (2 Pt 1): e19
73. Fraaij PL, Bergshoeff AS, van Rossum AM, et al. Changes in indinavir exposure over time: a case study in six HIV-1-infected children. J Antimicrob Chemother 2003; 52 (4): 727-30 (Pubitemid 37258444)
74. Grub S, Delora P, Ludin E, et al. Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection. Clin Pharmacol Ther 2002; 71 (3): 122-30 (Pubitemid 34271115)
75. Puthanakit T, Chokephaibulkit K, Suntarattiwong P, et al. Therapeutic drug monitoring of lopinavir in human immunodeficiency virus-infected children receiving adult tablets. Pediatr Infect Dis J 2010; 29 (1): 79-82
76. Rakhmanina N, van den Anker J, Baghdassarian A, et al. Population pharmacokinetics of lopinavir predict suboptimal therapeutic concentrations in treatment-experienced human immunodeficiency virus-infected children. Antimicrob Agents Chemother 2009; 53 (6): 2532-8
77. Robbins BL, Capparelli EV, Chadwick EG, et al. Pharmacokinetics of highdose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors. Antimicrob Agents Chemother 2008; 52 (9): 3276-83
78. Neely M, Rakhmanina N. Pharmacokinetic optimization of antiretroviral therapy in children and adolescents. Clin Pharmacokinet 2011 Mar 1; 50 (3): 143-89
79. Vermeiren H, Van Craenenbroeck E, Alen P, et al. Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling. J Virol Methods 2007; 145 (1): 47-55 (Pubitemid 47247892)
80. Stanford University. HIV drug resistance database [online]. Available from URL: http://hivdb.stanford.edu [Accessed 2011 Mar 31]
81. International AIDS Society. Update of the drug resistance mutations in HIV-1: December 2010 [online]. Available from URL: . org/resistance-mutations/ mutations-figures.pdf [Accessed 2011 Mar 31]
82. Rakhmanina N, van den Anker J, Baghdassarian A, et al. The phenotypic and genotypic susceptibility lopinavir scores and virologic response in treatmentexperienced children with HIV [abstract no. 0-17]. 10th International Workshop on Clinical Pharmacology of HIV Therapy; 2009Apr 15-17;Amsterdam
83. Dieleman JP, Gyssens IC, van der Ende ME, et al. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS 1999; 13 (4): 473-8
84. Solas C, Basso S, Poizot-Martin I, et al. High indinavir Cmin is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen. J Acquir Immune Defic Syndr 2002; 29 (4): 374-7 (Pubitemid 34288891)
85. Rodriguez-Novoa S, Barreiro P, Rendon A, et al. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C->T polymorphism at the multidrug resistance gene 1. Clin Infect Dis 2006; 42 (2): 291-5 (Pubitemid 43054206)
86. Molto J, Santos JR,Valle M, et al. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice. Ther Drug Monit 2007; 29 (5): 648-51 (Pubitemid 47494066)
87. Rakhmanina N, van Rongen A, van den Anker J, et al. Plasma protease inhibitor concentrations and fasting lipid profiles in HIV-infected children [abstract no. 006]. 11th International Workshop on Clinical Pharmacology of HIV Therapy; 2010 Apr 7-9; Sorrento
88. Abel S, Back DJ, Vourvahis M. Maraviroc: pharmacokinetics and drug interactions. Antivir Ther 2009; 14 (5): 607-18
89. Long MC, King JR, Acosta EP. Pharmacologic aspects of new antiretroviral drugs. Curr HIV/AIDS Rep 2009; 6 (1): 43-50
90. Nachman S, Acosta E, Samson P, et al. Interim Results from IMPAACT P1066: raltegravir oral chewable tablet formulation in children 6 to 11 years [abstract no. 161LB]. 17th Conference on Retroviruses and Opportunistic Infections; 2010 Feb 16-19; San Francisco (CA)
91. Brainard DM, Wenning LA, Stone JA, et al. Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor. J Clin Pharmacol. Epub 2011 Jan 5
92. Bowen A, Palasanthiran P, Sohn AH. Global challenges in the development and delivery of paediatric antiretrovirals. Drug Discov Today 2008; 13 (11-12): 530-5
93. Strickley RG, Iwata Q, Wu S, et al. Pediatric drugs: a review of commercially available oral formulations. J Pharm Sci 2008; 97 (5): 1731-74
94. RxList: the Internet drug index [online]. Available from URL: http:// www.rxlist.com [Accessed 2011 Mar 11]
95. Meadway J. Helping children take HAART adherence, taste and formulations [online]. Available from URL: www.i-base.info/pub/paed/help.html [Accessed 2011 Mar 22]
96. University of Washington. FDA-approved antiretrovirals for HIV [online]. Available from URL: Teachdocs/HAART.pdf [Accessed 2011 Mar 22]
97. Winnick S, Lucas DO, Hartman AL, et al. How do you improve compliance? Pediatrics 2005; 115 (6): e718-24
98. Heald AE, Pieper CF, Schiffman SS. Taste and smell complaints in HIVinfected patients. AIDS 1998; 12 (13): 1667-74 (Pubitemid 28418338)
99. Gibb DM, Goodall RL, Giacomet V, et al. Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial. Pediatr Infect Dis J 2003; 22 (1): 56-62 (Pubitemid 36091779)
100. Pontali E. Facilitating adherence to highly active antiretroviral therapy in children with HIV infection: what are the issues and what can be done? Paediatr Drugs 2005; 7 (3): 137-49 (Pubitemid 41019940)
101. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000 Jun; 30 Suppl. 2: S171-6 (Pubitemid 32268984)
102. Byrne M, Honig J, Jurgrau A, et al. Achieving adherence with antiretroviral medications for pediatric HIV disease. AIDS Read 2002; 12 (4): 151-4, 161-4
103. Gavin PJ, Yogev R. The role of protease inhibitor therapy in children with HIV infection. Paediatr Drugs 2002; 4 (9): 581-607 (Pubitemid 34983405)
104. Van Dyke RB, Lee S, Johnson GM, et al. Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. Pediatrics 2002; 109 (4): e61
105. Goode M, McMaugh A, Crisp J, et al. Adherence issues in children and adolescents receiving highly active antiretroviral therapy. AIDS Care 2003; 15 (3): 403-8 (Pubitemid 36718398)
106. Reddington C, Cohen J, Baldillo A, et al. Adherence to medication regimens among children with human immunodeficiency virus infection. Pediatr Infect Dis J 2000; 19 (12): 1148-53 (Pubitemid 32003357)
107. Matsui D, Barron A, Rieder MJ. Assessment of the palatability of antistaphylococcal antibiotics in pediatric volunteers. Ann Pharmacother 1996; 30 (6): 586-8 (Pubitemid 26184408)
108. Powers JL. Properties of azithromycin that enhance the potential for compliance in children with upper respiratory tract infections. Pediatr Infect Dis J 1996; 15 (9 Suppl.): S30-7
109. Powers JL, Gooch 3rd WM, Oddo LP. Comparison of the palatability of the oral suspension of cefdinir vs. amoxicillin/clavulanate potassium, cefprozil and azithromycin in pediatric patients. Pediatr Infect Dis J 2000; 19 (12 Suppl.): S174-80 (Pubitemid 32001766)
110. Sjovall J, Fogh A, Huitfeldt B, et al. Methods for evaluating the taste of paediatric formulations in children: a comparison between the facial hedonic method and the patients own spontaneous verbal judgement. Eur J Pediatr 1984; 141 (4): 243-7 (Pubitemid 14193912)
111. Cruz GE, Cruz FC, Bernardes LM, et al. Caregivers of children with HIV/AIDS: revealing the meaning behind adherence to HAART [abstract no. MOPE0207]. XVII International AIDS Conference; 2008 Aug 3-8; Mexico City
112. NIH Working Group on Antiretroviral Therapy and Medical Management of HIV Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection: National Resource Center at the Francois-Xavier Bagnoud Center, UMDNJ. The Health Resources and Services Administration, and The National Institutes of Health, 2005
113. King JR, Kimberlin DW, Aldrovandi GM, et al. Antiretroviral pharmacokinetics in the paediatric population: a review. Clin Pharmacokinet 2002; 41 (14): 1115-33 (Pubitemid 35398689)
114. Rakhmanina NY, van den Anker JN, Soldin SJ, et al. Can therapeutic drug monitoring improve pharmacotherapy of HIV infection in adolescents? Ther Drug Monit 2010; 32 (3): 273-81
115. Bunupuradah T, Wannachai S, Chuamchaitrakool A, et al. Use of tastemasking product, FLAVORx, to assist Thai children to ingest generic antiretrovirals. AIDS Res Ther 2006; 3: 30-5
116. Garvie PA, Lensing S, Rai SN. Efficacy of a pill-swallowing training intervention to improve antiretroviral medication adherence in pediatric patients with HIV/AIDS. Pediatrics 2007; 119 (4): e893-9 (Pubitemid 46556653)
117. Baylor International Pediatric AIDS Initiative. Pill swallowing program video [online]. Available from URL: [Accessed 2010 Nov 13]
118. Committee on Pediatric AIDS, Section on International Child Health. Increasing antiretroviral drug access for children with HIV infection. Pediatrics 2007; 119 (4): 838-45
119. Mennella JA, Beauchamp GK. Optimizing oral medications for children. Clin Ther 2008 Nov; 30 (11): 2120-32
120. Douroumis D. Practical approaches of taste masking technologies in oral solid forms. Expert Opin Drug Deliv 2007; 4 (4): 417-26 (Pubitemid 47249139)
121. Ayenew Z, Puri V, Kumar L, et al. Trends in pharmaceutical taste masking technologies: a patent review. Recent Pat Drug Deliv Formul 2009; 3 (1): 26-39
122. Jaderlund C. The impact of a commercially available medication flavoring system (FLAVORx) on pediatric inpatients admitted to a childrens hospital. 14th Pediatric Pharmacy Conference: Pediatric Pharmacy Advocacy Group Annual Meeting; 2005 Oct 9-12; Chicago (IL)
123. Chiappetta DA, Hocht C, Sosnik A. A highly concentrated and taste-improved aqueous formulation of efavirenz for a more appropriate pediatric management of the anti-HIV therapy. Curr HIV Res 2010; 8 (3): 223-31
124. Shingadia D, Viani RM, Yogev R, et al. Gastrostomy tube insertion for improvement of adherence to highly active antiretroviral therapy in pediatric patients with human immunodeficiency virus. Pediatrics 2000; 105 (6): e80
125. Barigye H, Luyirika E. The challenges of paediatric ARV formulations in resource-poor countries: the Ugandan experience [abstract no. 1080]. Second IAS Conference on HIV Pathogenesis and Treatment; 2003 Jul 13-16; Paris
126. OBrien DP, Sauvageot D, Zachariah R, et al. In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy. AIDS 2006; 20 (15): 1955-60 (Pubitemid 44427613)
127. Corbett AH, Hosseinipour MC, Nyirenda J, et al. Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children. Antivir Ther 2010; 15 (1): 83-90
128. Caldwell SM, Raitt JR. Oral medication administration: implications caused by capsule splitting. J Am Pharm Assoc (2003) 2010; 50 (4): 532-3
129. Hill SW, Varker AS, Karlage K, et al. Analysis of drug content and weight uniformity for half-tablets of 6 commonly split medications. J Manag Care Pharm 2009; 15 (3): 253-61
130. Teng J, Song CK, Williams RL, et al. Lack of medication dose uniformity in commonly split tablets. J Am Pharm Assoc (Wash) 2002; 42 (2): 195-9
131. Noviasky J, Lo V, Luft DD, et al. Clinical inquiries: which medications can be split without compromising efficacy and safety? J Fam Pract 2006; 55 (8): 707-8 (Pubitemid 44699414)
132. Margiocco ML, Warren J, Borgarelli M, et al. Analysis of weight uniformity, content uniformity and 30-day stability in halves and quarters of routinely prescribed cardiovascular medications. J Vet Cardiol 2009; 11 (1): 31-9
133. Rosenberg JM,Nathan JP, Plakogiannis F. Weight variability of pharmacistdispensed split tablets. J Am Pharm Assoc (Wash) 2002; 42 (2): 200-5
134. Quinzler R, Haefeli WE. Tablet splitting [in German]. Ther Umsch 2006 Jun; 63 (6): 441-7 (Pubitemid 43954561)
135. Diep H, Best B, Capparelli E, et al. Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children [abstract no. 877]. 17th Conference on Retroviruses andOpportunistic Infections; 2010Feb 16-19; San Francisco (CA)
136. Damle BD, Yan JH, Behr D, et al. Effect of food on the oral bioavailability of didanosine from encapsulated enteric-coated beads. J Clin Pharmacol 2002; 42 (4): 419-27 (Pubitemid 34259776)
137. Phelps BR, Hathcock SJ, Werdenberg J, et al. Experiencing antiretroviral adherence: helping healthcare staff better understand adherence to paediatric antiretrovirals. J Int AIDS Soc 2010; 13: 48-52
138. Kiruthi H, Rakhmanina N, Eldridge N, et al. The important role of the clinical pharmacist as part of multidisciplinary approach to the treatment of HIVinfected pediatric patients [abstract no. 3.12]. 6th InternationalWorkshop on Clinical Pharmacology of HIV Therapy; 2005 Apr 28-30; Quebec
139. United Nations Childrens Fund (UNICEF). Procurement services: commodities and supply services [online]. Available from URL: . unicef.org/videoaudio/PDFs/ CommodityEnglish.pdf [Accessed 2011 Jan 1]
140. Rakhmanina NY, van den Anker JN. Treating an HIV-infected paediatric patient: an easy task? Antivir Ther 2010; 15 (3): 293-6
141. LHomme RF, Kabamba D, Ewings FM, et al. Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets. AIDS 2008; 22 (5): 557-65 (Pubitemid 351640588)